Background: people with dementia (PWD), and their carers, face challenges with medicines management activities. As interventions to support medicines management for PWD are developed, consideration must be given to the outcomes chosen to measure their effectiveness. A Core Outcome Set (COS) is a minimum set of outcomes to be measured in all trials in a particular clinical area, which seeks to reduce heterogeneity of outcome reporting across trials. Objective: to develop a COS for trials assessing the effectiveness of medicines management interventions for PWD in primary care. Methods: a comprehensive list of outcomes was compiled through a systematic review and semi-structured interviews with PWD (n = 18), their carers (n = 15), community pharmacists (n = 15) and general practitioners (n = 15). These outcomes were rated by a Delphi panel (n = 52) on a nine-point Likert scale from 1 (limited importance) to 9 (critical) during three sequential rounds of questionnaire distribution. The Delphi panel comprised participants with expertise in dementia and medicines management, including academics and healthcare professionals. An outcome was eligible for inclusion in the COS if ≥70% of participants rated it critical and <15% of participants rated it of limited importance. Results: twenty-nine outcomes identified from the systematic review and stakeholder interviews were presented to the Delphi panel. Consensus was reached on 21 outcomes, of which the 7 most highly rated were recommended for inclusion in the COS. Conclusion: this study used robust methodology to develop a COS for medicines management interventions for PWD. Future work should identify the most appropriate tools to measure these outcomes.
• This may be achieved through the use of Core Outcome Sets.
• This study achieved consensus on 21 outcomes.
• We recommend the 7 most highly rated outcomes should be measured in future trials in this area.
Introduction
Medicines management is a complex process for people with dementia (PWD), who often suffer with other comorbidities and are frequently prescribed multiple regular medicines [1] [2] [3] . It presents particular challenges to community-dwelling PWD, along with their carers. Medicines management has been defined as 'the entire way in which a medicine is procured, delivered, prescribed, administered and reviewed to optimise the contribution that they make to producing informed and desired outcomes of patient care' [4] .
A systematic review conducted by the authors demonstrated a lack of randomised controlled trials (RCTs) examining the effectiveness of medicines management interventions for PWD and highlighted the minimal overlap in outcomes between the three included studies [5] . With the increase in community-dwelling PWD, the literature has emphasised the importance of developing primary carebased interventions to improve medicines management for PWD [6] . As these interventions are developed, it is imperative that there is adequate means by which to compare their effectiveness. The Core Outcome Measures for Effectiveness Trials (COMET) initiative advocates the use of a Core Outcome Set (COS) to address this issue. A COS is defined as the minimum set of outcomes to be measured in all trials conducted in a particular area of healthcare [7] . To date, several COSs aimed at PWD have been developed or are under development [8, 9] , however no COSs have targeted medicines management in this population. Therefore, the aim of this study was to develop a COS applicable to all trials assessing the effectiveness of medicines management interventions for PWD in primary care.
Methods
Development of the COS was guided by the approach suggested by the COMET initiative [7, 10] , and reported according to the COS-STAR guidelines [11] . This involved two phases; Phase 1-generating and refining a comprehensive list of outcomes, and Phase 2-a Delphi consensus exercise. The scope of the COS was clearly defined prior to its development, to be relevant to all medicines management interventions (i.e. those incorporating prescribing, dispensing, adherence and/or medication review) for PWD in primary care.
Phase 1: generating and refining a comprehensive list of outcomes
The aim of this phase was to identify a comprehensive list of outcomes to be presented to the Delphi panel in Phase 2. This phase involved three steps, as described below.
Identification of outcomes from the literature
A systematic review of the literature was completed to identify RCTs evaluating the effectiveness of medicines management interventions for PWD. The full details of the review are reported elsewhere [5] . Outcomes were extracted from three studies included in this review, and two additional study protocols.
Semi-structured interviews with key stakeholders
As part of a larger study which sought to develop an intervention focusing on medicines management for PWD in primary care, semi-structured interviews were carried out with PWD (n = 18), carers (n = 15), general practitioners (GPs) (n = 15) and community pharmacists (n = 15). During these interviews, participants were asked to consider outcomes of importance for future interventions, and data from this question was extracted. Ethical approval was obtained from the National Research Ethics Service (NRES) Committee-Cambridgeshire and Hertfordshire (Ref: 15/EE/0103).
Initial refinement of outcomes by project management group
Outcomes derived from the systematic review and stakeholder interviews were included in a draft list of potential outcomes. This list was reviewed by members of the Project Management Group (PMG; all authors) to refine the outcomes into a comprehensive list to be included in the final questionnaire.
Phase 2: Delphi consensus exercise
The aim of this phase of the study was to condense the outcomes derived from Phase 1, through a Delphi consensus exercise, using sequential questionnaires. Ethical approval was obtained from Queen's University Belfast School of Pharmacy Ethics Committee (Ref: 020PMY2016).
Recruitment of the Delphi panel
For this phase, participants included healthcare professionals (HCPs) from primary and secondary care, academics and researchers with expertise in dementia, care of older people and medicines management. Potential participants were sought through personal contacts of the PMG. Academics and researchers were also identified from relevant academic journals. In addition, researchers involved in the development of other COSs for older people or PWD were identified through the COMET database. A snowball sampling technique was also employed where those approached to participate were invited to suggest colleagues whom they considered suitable for inclusion in the Delphi panel [12] .
Potential participants were initially contacted via an email which invited them to take part in the Delphi consensus exercise, and to which an information sheet regarding the study was attached. They were contacted within a week of the initial email to confirm if they wished to participate. At this stage, they were asked to complete a consent form electronically, and were formally enrolled in the study.
The Delphi questionnaire
The study consisted of three sequential rounds of questionnaires (distributed November 2016, January 2017 and March 2017) with group and individual feedback provided to participants in Rounds 2 and 3. Group feedback was embedded within subsequent questionnaires, to inform respondents of the overall views of participants. Individual feedback was provided to participants via email prior to completing the next round, and served as a reminder of participants' previous answers. Each questionnaire was distributed via an email containing a link which brought participants to a web-based survey tool (SurveyGizmo ® ). Participants were provided with background information about the study, and instructions to aid completion of the questionnaire. Participants were given 3 weeks to complete each round, and the time interval between rounds was approximately 6 weeks. Reminder emails were sent between rounds to encourage completion.
Round 1 collected demographic information about respondents. Participants were then presented with the list of outcomes and asked to rate the importance of each outcome. Guidance issued by COMET recommends the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group scale for rating outcomes in a consensus exercise for developing COSs [7, 13] . This was presented as a numerical scale from 1 to 9, divided into three categories, in which scores of 1-3 represented outcomes of 'limited importance', 4-6 represented 'important but not critical' outcomes and 7-9 represented 'critical' outcomes [7, 13] . During Round 1, participants were given the opportunity to suggest any additional outcomes which had not been identified in the presented list of outcomes. Analysis of Round 1 consisted of calculating the distribution of scores, i.e. the percentage of participants that rated the outcome at each score. Outcomes suggested by participants were extracted and reviewed by members of the PMG to remove duplicate outcomes and outcomes beyond the scope of the COS. Round 2 questionnaires consisted of all the outcomes included in the Round 1, along with additional outcomes suggested by the panel in Round 1. Participants were asked to rate outcomes again, considering the group responses and their own previous responses. As for Round 1, the distribution of scores was calculated. Round 3 questionnaires contained only those outcomes for which the criteria for consensus (see below ) had not yet been reached, and as for the previous rounds, participants were asked to rate outcomes again.
Data analysis
Criteria for consensus in the COS were decided a priori, based on thresholds recommended by COMET [7] . Consensus was reached on inclusion of an outcome in the COS ('consensus in'), after Round 2 or Round 3, when 70% or more participants scored the outcome between 7 and 9, and <15% of participants scored the outcome between 1 and 3 [7] . Consensus was reached for exclusion of an outcome from the COS ('consensus out') after Round 2 or Round 3, when 70% or more of participants had scored the outcome between 1 and 3, and <15% of participants had scored the outcome between 7 and 9 [7, 10] . Any other scores were classified as 'no consensus', and hence, these outcomes were not eligible for inclusion in the COS [7] .
Given that one advantage of a COS is the potential to reduce heterogeneity in outcome reporting in systematic reviews, we prioritised the seven most highly ranked outcomes, in line with the median number of outcomes reported in Cochrane systematic reviews [10] . This was analysed based on the percentage of participants rating each outcome 'critical'.
Results

Phase 1: generating and refining a comprehensive list of outcomes
The literature review identified 27 distinct outcomes across five studies [5] . Semi-structured interviews identified 17 different outcomes. A range of outcomes were suggested by HCPs, however, the only outcomes suggested by PWD and carers were improvement in patient and/or carer knowledge of medication. Overall, 46 outcomes were identified from the systematic review and stakeholder interviews. Duplicate outcomes were removed, along with those outside the scope of the COS; related outcomes were collated, leaving 29 outcomes eligible for inclusion in the consensus exercise. These outcomes, along with their definitions, were considered by the PMG, and wording was changed where appropriate. Outcomes were grouped into 'domains' derived from the Cochrane Effective Practice and Organisation of Care (EPOC) Group and included: medication-related outcomes, patient-related outcomes, use and access to services, resource use, social outcomes, adverse effects or harms, knowledge and satisfaction [14] .
Phase 2: Delphi consensus exercise
A total of 114 potential participants were invited to take part in the study, of whom 52 (46%) completed the consent form and were enrolled in the study. The demographics of participants are detailed in Table 1 .
There were 48 respondents to Round 1 (92%). During Round 1, an additional 32 outcomes were suggested by participants. Each of these outcomes was discussed amongst the PMG for consideration for inclusion in Round 2. Of these, four outcomes (depression, anxiety, anticholinergic burden and all-cause mortality) were included in Round 2 questionnaires, along with all the outcomes included in Round 1. All respondents to Round 1 were invited to take part in Round 2, and 47 participated (98%). At this stage, 17 outcomes met the criteria for 'consensus in' and were not included in Round 3. Therefore, Round 3 questionnaires consisted of the 16 outcomes for which consensus had not yet been reached. As before, all respondents to Round 2 were invited to take part in Round 3 and 44 participated (94%). 'Consensus in' was reached for an additional four outcomes, with 'no consensus' reached on the remaining twelve outcomes. The distribution of scores for each round is detailed in Table 2 . This resulted in 21 outcomes meeting the criteria for consensus for inclusion in the COS (Table 3) . Of these, the seven highest-ranking outcomes were: medication side effects, adverse drug events, medication appropriateness, falls, behavioural and psychological symptoms of dementia, acceptability of the intervention to patients, carers and stakeholders, and quality of life.
Discussion
In this study, consensus was reached on 21 outcomes, of which the 7 most highly rated were recommended for inclusion in the COS. It is envisaged that these outcomes will be used by future trialists to assess the effectiveness of future interventions within the scope of the COS.
The outcomes included in this COS adequately capture the current challenges faced by PWD, their carers and HCPs. Given the medicine-centred scope of the COS it is unsurprising medication-related outcomes were rated highly by the Delphi panel. Of note, only one medication-related outcome did not meet the criteria for inclusion in the COSnumber of medicines prescribed. This is interesting, considering polypharmacy (i.e. the use of four or more medicines) is prevalent in this population, and associated with negative outcomes [15, 16] . However, in recent years there has been a shift in focus from the number of medicines prescribed to the appropriateness of those medicines [17] . This has been reflected in our COS, with medication appropriateness being the third most highly rated outcome. Where medicines have been prescribed in accordance with the best available evidence and are suitable for a patient, in view of their medical history and comorbidities Appropriateness of psychotropic drug use-these include any drugs that alter the mind, emotion or behaviour, for example antipsychotics, sedatives and anti-anxiety drugs The effect of a drug can be changed by another drug, herbal medicine, food or drink, and this can lead to a change or complication in the patient's condition A side effect can be described as an undesirable effect of a medicine Any difficulties relating to prescribing, dispensing, supply, administration, adherence and medication review The extent to which a person's medication-taking corresponds to agreed recommendations from a healthcare provider The cumulative effect of taking multiple medicines with anticholinergic properties Patient-related outcomes This study has several strengths, including the robust methodology followed, in accordance with guidance issued by COMET [7] , and was reported as recommended by the COS-STAR statement (Supplementary Table S1 ) [11] . The Delphi panel included participants from a range of countries, which enhances the generalisability of our COS beyond the UK. Similarly, stakeholders from both healthcare and research backgrounds were included. The relatively low drop-out rate between each round was a further strength of the study, reducing the potential for attrition bias [18] .
A limitation was the exclusion of patients and carers from the Delphi panel. Whilst the COMET initiative advises the inclusion of patients in COS development, no specific guidance exists on how they should be involved [10] . Importantly, the scope of the COS will influence the nature of patient involvement. Considering the cognitive decline inherent with dementia, we considered qualitative interviews to be the most appropriate method for inclusion of patients and their carers in this COS. However, the only outcomes suggested by these participants during interviews ('patient knowledge' and 'carer knowledge') did not meet the criteria for consensus during the Delphi exercise. Therefore, the relevance of our COS beyond HCPs and researchers cannot be assured. Despite this, it is important to remember that a COS is only a minimum set of outcomes, with trialists free to consider other outcomes where appropriate. Future work should endeavour to determine the most appropriate ways to involve vulnerable groups of patients in COS development.
We recognise that the inclusion of 21 outcomes in a COS may be counterintuitive to a process aimed at developing a 'minimum' set of outcomes. This is not unique to our study, with several recently published COSs exhibiting similarly large numbers of outcomes [19] [20] [21] . For this reason, priority was given to the seven highest-ranking outcomes, based on recommendations from COMET and Cochrane [10, 22] . It may be prudent for future COS developers to consider the thresholds for inclusion and exclusion, and make the decision to change the percentage agreement for consensus if required. Increasingly, COS developers are conducting faceto-face consensus meetings, following a Delphi panel, to finalise the COS [23, 24] . Due to time and financial constraints we did not employ this method, however, it is possible a consensus meeting may have reduced the COS further and should be considered by future COS developers.
It is envisaged this COS will provide direction in what to measure in future trials conducted in medicines management for PWD. However, it must be emphasised that this work does not provide recommendations on how to measure these outcomes. Consistent use of outcomes across similar trials will only be valuable if there is also consistency in the tools used to measure them [7, 10, 25] . Therefore, future research must determine the most appropriate tools to measure each of the outcomes presented in this COS. This process can be supported by the COSMIN (COnsensus-based Standard for the selection of health status Measurement INstruments) checklist [25] .
Conclusion
This study has led to the development of a COS for use in trials assessing the effectiveness of interventions to improve medicines management for PWD. Consensus was reached for a total of 21 outcomes, and we recommend that the seven highest-ranking outcomes are included in the COS. Future work must determine the most appropriate methods for measuring the outcomes included in this COS.
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